(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

TERAPIA DE COMBINAÇÃO COM ANTAGONISTA DE LIV1-ADC E PD1

ArquivadaInvention PatentPCT · US2020063976

Application data

Number

112022011268

Type

Invention Patent

Filing

12/09/2020

Publication

09/06/2022

PCT

US2020063976

Progress at the INPI

  1. Filing12/09/20
  2. Publication09/06/22
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 12/09/2020 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 03/05/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

MERCK SHARP & DOHME B.V.

NL

SEAGEN INC.

US

See this company's full portfolio

Inventors

D. S. (pessoa física)

US

N. C. (pessoa física)

US

Z. W. (pessoa física)

US

Technical data

IPC Classification

Priority claims

US

62/945,885 · 12/09/2019

US

63/031,528 · 05/28/2020

US

63/076,664 · 09/10/2020

US

63/110,692 · 11/06/2020

Abstract

TERAPIA DE COMBINAÇÃO COM ANTAGONISTA DE LIV1-ADC E PD-1. A presente divulgação refere-se, em geral, a métodos para o tratamento de cânceres que expressam LI V-1 compreendendo a administração de um conjugado anticorpo-fármaco anti-LI V-1 (LI V-1 - ADC) em combinação com um antagonista de PD-1, tal como um anticorpo anti-PD-1.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

03/05/2024

RPI 2774

Arquivamento - Art. 33 da LPI

#11.1

12/19/2023

RPI 2763

Notificação de entrada na fase nacional - PCT

#1.3

09/06/2022

RPI 2696

Alteração de dados cadastrais

#1.1

06/21/2022

RPI 2685

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.